No Data
No Data
Guohai Securities released a research report on April 21 stating that it gave Walter Dyne (000915.SZ) a purchase rating. The main reasons for the rating include: 1) strong R&D strength, focusing on the field of child health; 2) intelligent upgrading promo
Guohai Securities released a research report on April 21 stating that it gave Walter Dyne (000915.SZ) a purchase rating. The main reasons for the rating include: 1) strong R&D strength, focusing on the field of child health; 2) intelligent upgrading promotes production chain optimization and production capacity improvement. (Mainichi Keizai Shimbun)
Walter Dyne (000915): Continued development of new products, steady growth in performance
Incident: On April 18, 2024, Walter released its report for the first quarter of 2024: the company achieved revenue of 572 million yuan in the first quarter of 2024, an increase of 1.85% over the previous year; achieved a net profit of 1.69 million yuan
Express News | Walter Dyne: Net profit of 169 million yuan in the first quarter of 2024 increased 3.0% year-on-year
Walter Dyne (000915) 2023 Annual Report Review Report: Rich Product Layout, Steady Performance Growth
Incident: Walter released its 2023 annual report on March 16, 2024: In 2023, the company achieved revenue of 2,484 billion yuan, an increase of 6.11% over the previous year; achieved net profit of 585 million yuan to mother.
Waltdyne (000915.SZ) children's drugs mainly include iKexin vitamin AD drops, edicine, desloratadine oral solution, etc.
Gelonghui, March 19 | Walter Dyne (000915.SZ) said on the investor interactive platform that the company's children's drugs mainly include iKexin vitamin AD drops, eDexin, dyne iron, dyne calcium, dyne zinc, oral rehydration solution, pediatric ibuprofen suppositories, atomoxetine hydrochloride oral solution, and desloratadine oral solution. Among them, Icexin Vitamin AD drops had the largest sales of all products. “Yikexin” is a well-known trademark in China and has been ranked first in the market share of similar products for many years.
Walter Dyne (000915): Optimistic about high dividends, new volume, and steady growth
Key investment points In 2023, the company will continue to focus on the main pharmaceutical industry. We are optimistic about the company's core products (iKexin) and key second-tier products (dyne iron, dyne calcium, pediatric ibuprofen suppositories, etc.) channel expansion and continuous improvement in penetration rate, and the product matrix will continue to be rich
No Data